Tele-ICU for patients after cardiac surgery: experience from the TELESCOPE trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Remote Intensive Care Unit Monitoring for Post-Cardiac Surgery Patients: Insights from the TELESCOPE Study

  • By

  • Tarso Augusto Duenhas Accorsi

  • Renato Carneiro de Freitas Chaves

  • Carlos Henrique Sartorato Pedrotti

  • Danilo Teixeira Noritomi

  • Otavio Tavares Ranzani

  • Adriano José Pereira

  • September 29, 2026

Share

  • 1

    The TELESCOPE trial evaluated tele-ICU support for cardiac surgery patients in 30 Brazilian public hospital ICUs.

  • 2

    Tele-ICU exposure was associated with a 17.4% shorter ICU length of stay and earlier discharge readiness after adjustment.

  • 3

    ICU mortality was 3.9% in tele-ICU units compared to 9.6% in control units, with adjusted odds ratios indicating significant differences.

  • 4

    In-hospital mortality rates were 7.8% for tele-ICU patients versus 13.8% for standard care, also showing significant adjusted differences.

  • 5

    Findings from the cardiac surgery cohort were post hoc and involved few centers, necessitating cautious interpretation and further evaluation.

Original Source(s)

Tele-ICU for patients after cardiac surgery: experience from the TELESCOPE trial

  • by Tarso Augusto Duenhas Accorsi, Renato Carneiro de Freitas Chaves, Carlos Henrique Sartorato Pedrotti, Danilo Teixeira Noritomi, Otavio Tavares Ranzani, Adriano José Pereira

  • September 29, 2026

Related Content

Heartbeat-powered pacemaker may pave way for self-sustaining devices

A triboelectric nanogenerator–supported pacemaker shows efficacy in a preclinical swine study.

May Lower RFR Signal Repeat Revascularization?

Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.

Acute Kidney Injury Therapies Reviewed

Several interventions show early promise in high-risk patients, yet the field still awaits its first proven targeted therapy.